相关临床试验
11
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
7
63.6%
尚未招募
3
27.3%
终止
1
9.1%
暂无批准数据
- A comprehensive pipeline analysis reveals over 5 companies developing novel treatments for Cannabis Use Disorder (CUD), with AEF0117 by Aelis Farma representing a promising new pharmacological class in clinical trials. - The CUD therapeutic landscape includes drugs across multiple development stages from discovery to Phase III, with various routes of administration including oral, intravenous, subcutaneous, parenteral, and topical formulations. - Key players such as Aelis Farma, Anebulo Pharmaceuticals, and Indivior are advancing promising products like AEF0117, ANEB-001, and INDV-5004 through different phases of clinical development. - The pipeline assessment highlights significant collaborative efforts, acquisition activities, and licensing agreements aimed at addressing the critical unmet medical needs in cannabis use disorder treatment.
• Aelis Farma's AEF0117 did not meet its primary endpoint of reducing cannabis use to one day or less per week in patients with moderate to severe cannabis use disorder (CUD). • The Phase 2B trial also failed to meet secondary endpoints, including complete cessation of marijuana use or reduction to two days or less per week. • Indivior, which had an option to license AEF0117, announced it does not currently expect to exercise this option due to the lack of separation from placebo in the trial. • AEF0117 was well-tolerated, with adverse events similar across treatment groups, including placebo, indicating no significant safety concerns.
